IP Library › Granted Patent US 12,378,581
Granted Patent B2
US 12,378,581 · App. 18/317,588 · Granted Aug 5, 2025

Compositions and methods for metabolic control of a biofermentation process with synthetic metabolic valves

Inventors: Michael David Lynch (Durham, NC); Zhixia Ye (Raleigh, NC)
Assignee: Duke University
C12P7/42C12N9/0006C12N9/0008C12N9/001C12N9/0016C12N9/0051C12N9/1025C12N15/746C12P13/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,581
App. No.
18/317,588
Granted
Aug 5, 2025
Kind
B2
Abstract

The present disclosure provides compositions and methods for rapid production of chemicals in genetically engineered microorganisms in a large scale. Also provided herein is a high-throughput metabolic engineering platform enabling the rapid optimization of microbial production strains. The platform, which bridges a gap between current in vivo and in vitro bio-production approaches, relies on dynamic minimization of the active metabolic network.

Claims (17)

1. A genetically modified microorganism comprising:

i. a production pathway comprising at least one production enzyme for biosynthesis of a product selected from the group: an amino acid, acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutryate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, adipic acid, propanol, isopropanol, fused alcohols, 1,2-propanediol, 1,3-propanediol, formate, fumaric acid, propionic acid, succinic acid, valeric acid, maleic acid, or poly-hydroxybutyrate; and

ii. one or more synthetic metabolic valves for reducing or eliminating flux through multiple metabolic pathways within the genetically modified microorganism when the synthetic metabolic valves are induced, the one or more synthetic metabolic valves comprising:

a) at least one silencing synthetic metabolic valve that silences gene expression of a gene selected from: fabI, gltA, lpd, zwf, and udhA, or

b) at least one proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme selected from: fabI, gltA, lpd, zwf, and udhA; and

wherein growth of the genetically modified microorganism is slowed or stopped and product production is enhanced, as compared to a microorganism lacking the production pathway or synthetic metabolic valve, by inducing the synthetic metabolic valve, and

wherein growth of the genetically modified microorganism is slowed or stopped by depletion of a limiting nutrient thereby inducing a stationary phase, and product production is enhanced, as compared to a microorganism lacking the production pathway or synthetic metabolic valve, by inducing the synthetic metabolic valve in the stationary phase,

wherein the synthetic metabolic valve combination produces a genetically modified microorganism that is robust to changes in environmental conditions as evidenced by a robustness score greater than 0.6.

2. A genetically modified E. coli , comprising:

i. a production pathway comprising at least one production enzyme for biosynthesis of a product selected from the group: an amino acid, acetate, acetoin, acetone, acrylic, malate, fatty acid ethyl esters, isoprenoids, glycerol, ethylene glycol, ethylene, propylene, butylene, isobutylene, ethyl acetate, vinyl acetate, 1,4-butanediol, 2,3-butanediol, butanol, isobutanol, sec-butanol, butyrate, isobutyrate, 2-OH-isobutryate, 3-OH-butyrate, ethanol, isopropanol, D-lactate, L-lactate, pyruvate, itaconate, levulinate, glucarate, glutarate, caprolactam, adipic acid, propanol, isopropanol, fused alcohols, 1,2-propanediol, 1,3-propanediol, formate, fumaric acid, propionic acid, succinic acid, valeric acid, maleic acid, or poly-hydroxybutyrate; and

ii. one or more synthetic metabolic valves for reducing or eliminating flux through multiple metabolic pathways within the genetically modified E. coli when the one or more synthetic metabolic valves are induced, the one or more synthetic metabolic valves comprising:

a) at least one silencing synthetic metabolic valve that silences gene expression of a gene encoding at least one silenceable enzyme, or

b) at least one proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme; and

wherein growth of the genetically modified E. coli is slowed or stopped and product production is enhanced, as compared to E. coli lacking the production pathway or synthetic metabolic valve, by inducing the synthetic metabolic valve, and

wherein growth of the genetically modified microorganism is slowed or stopped by depletion of a limiting nutrient thereby inducing a stationary phase, and product production is enhanced, as compared to a microorganism lacking the production pathway or synthetic metabolic valve, by inducing the synthetic metabolic valve in the stationary phase,

wherein the synthetic metabolic valve combination produces a genetically modified microorganism that is robust to changes in environmental conditions as evidenced by a robustness score greater than 0.6.

3. The microorganism of claim 2 , wherein the silencing synthetic metabolic valve that silences gene expression of a gene is a gene selected from the group: fabI, gltA, ldp, zwf, or udhA; or the proteolytic synthetic metabolic valve that controls proteolysis of a proteolyzable enzyme is an enzyme selected from the group: fabI, gltA, ldp, zwf, or udhA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2023
From: LYNCH, MICHAEL; YE, ZHIXIA
To: DUKE UNIVERSITY
Reel/Frame 063652/0249 →
Continuity (4)
Continuation 17576290 · Jan 14, 2022
Continuation 16487542
Provisional Application 62461436 · Feb 21, 2017
Related Publication 20240035052A1 · Feb 1, 2024
References Cited (49)
US 8916358B2 · Swartz · 2014 [cited by applicant]
US 10036001B2 · Swartz · 2018 [cited by applicant]
US 10662426B2 · Lynch · 2020 [cited by applicant]
US 11193149B2 · Lynch · 2021 [cited by examiner]
US 11236370B2 · Lynch · 2022 [cited by examiner]
US 11268111B2 · Lynch · 2022 [cited by examiner]
US 11279956B2 · Lynch · 2022 [cited by examiner]
US 11339413B2 · Lynch · 2022 [cited by examiner]
US 11746362B2 · Lynch · 2023 [cited by examiner]
US 20110125118A1 · Lynch · 2011 [cited by applicant]
US 20110244575A1 · Lipscomb · 2011 [cited by applicant]
US 20120214170A1 · Moore · 2012 [cited by applicant]
US 20150072399A1 · Lynch et al. · 2015 [cited by applicant]
EP 2842542A1 · 2015 [cited by applicant]
WO 2012129450A1 · 2012 [cited by applicant]
WO 2013176772A1 · 2013 [cited by applicant]
WO 2014160025A1 · 2014 [cited by applicant]
WO 2015191638A1 · 2015 [cited by applicant]
WO 2018156646A1 · 2018 [cited by applicant]
Yuki Soma et al: “Metabolic flux redirection from a central metabolic pathway toward a synthetic pathway using a metabolic toggle switch”, Metabolic Engineering, vol. 23, May 1, 2014, pp. 175-184. [cited by applicant]
Kathleen E. McGinness et al: “Engineering Controllable Protein Degradation”, Molecular Cell., vol. 22, No. 5, Jun. 1, 2006, pp. 701-707. [cited by applicant]
Levchenko Igor et al: “A specificity-enhancing factor for the ClpXP degradation machine”, Science, vol. 289, No. 5488, Sep. 29, 2000, pp. 2354-2356. [cited by applicant]
Lynch et al., “Standarized two-stage bioprocess development using synthetic metabolic valves and dynamic metabolic control”, Abstracts of Papers ; ACS National Meeting & Exposition; 249th National Meeting and Exposition… [cited by applicant]
Brockman et al., “Dynamic knockdown of [cited by applicant]
Kim et al., “A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence”, Proc. Natl. Acad. Sci. USA (2013); vol. 110, pp. 19095-19100. [cited by applicant]
Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression,” Cell (2013); vol. 152, pp. 1173-1183. [cited by applicant]
Chica et al., “Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design” Curr Opin Biotechnol. Aug. 2005; 16(4):378-84. (Year: 2005). [cited by applicant]
Singh et al., “Protein Engineering Approaches in the Post-Genomic Era”, Curr Protein Pept Sci. 2017, 18, 1-11 (Year: 2017). [cited by applicant]
Kizer et al., “Application of Functional Genomics to Pathway Optimization for Increased Isoprenoid Production”, Appl Environ Microbial. May 2008;74(10):3229-41. (Year: 2008). [cited by applicant]
Prather et al., “De novo biosynthetic pathways: rational design of microbial chemical factories”, Curr Opin Biotechnol. Oct. 2008; 19(5):468-7 4. (Year: 2008). [cited by applicant]
Rath et al., Efficient programmable gene silencing by Cascade, Nucleic Acids Res. Jan. 9, 2015; 43(1): 237-246. (Year: 2015). [cited by applicant]
Lynch, “Into new territory: improved microbial synthesis through engineering of the essential metabolic network”, Curr Opin Biotechnol. Apr. 2016;38: 106-11. Epub Feb. 10, 2016. (Year: 2016). [cited by applicant]
Lee et al., “Aerobic production of alanine by [cited by applicant]
Kim et al., “Characterization of the L-alanine exporter AlaE of [cited by applicant]
Wang et al., “Improvement of NADPH bioavailability in [cited by applicant]
Vick et al., “ [cited by applicant]
Jan et al., “Metabolic Engineering and Transhydrogenase Effects on NADPH Availability in [cited by applicant]
Luo et al., “Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression”, Nucleic Acids Res. Jan. 9, 2015; 43(1): 674-681. (Year: 2015). [cited by applicant]
First Action Interview Pilot Program Pre-Interview Communication issued in U.S. Appl. No. 16/487,542 dated Nov. 23, 2020. [cited by applicant]
Final Office Action Communication issued in U.S. Appl. No. 16/487,542 dated Sep. 22, 2021. [cited by applicant]
Non-Final Office Action Communication issued in U.S. Appl. No. 16/487,542 dated Mar. 26, 2021. [cited by applicant]
International Search Report and Written Opinion issued in PCT application No. PCT/US2018/019040 mailing date Jun. 21, 2018. [cited by applicant]
International Preliminary Report on Patentability issued in PCT application No. PCT/US2018/019040 issue date Jun. 21, 2019. [cited by applicant]
Gustavsson M. et al: “Prospects of microbial cell factories developed through systems metabolic engineering”, Microbial Biotechnology, vol. 9, No. 5, Jul. 20, 2016, pp. 610-617. [cited by applicant]
Gong Z. et al: “Engineering Robustness of Microbial Cell Factories”, Biotechnology Journal, vol. 12, No. 1700014, Sep. 18, 2017, pp. 1-9. [cited by applicant]
Jiang T. et al: “Recent advances in improving metabolic robustness of microbial cell factories”, Current Opinion in Biotechnology, vol. 66, Jul. 16, 2020, pp. 69-77. [cited by applicant]
Olsson L. et al: “Robustness: linking strain design to viable bioprocesses”, Trends in Biotechnology, vol. 40, No. 8, Feb. 1, 2022, pp. 918-931. [cited by applicant]
Miziorko, H. M. “Enzymes of the mevalonate pathway of isoprenoid biosynthesis.” Archives of biochemistry and biophysics 505.2 (2011): 131-143. [cited by applicant]
Examination Report issued in Australian Patent Application No. 2022224766, dated Mar. 27, 2024. [cited by applicant]